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Abstract
Background: The safety of paediatric medications is paramount and contraindications provide clear pragmatic
advice. Further advice may be accessed through Summaries of Product Characteristics (SPCs) and relevant national
guidelines. The SPC can be considered the ultimate independent guideline and is regularly updated. In 2008, the
authors undertook a systematic review of the SPC contraindications of medications licensed in the United
Kingdom (UK) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). At that time, there were fewer
contraindications reported in the SPC for atomoxetine than methylphenidate and the specific contraindications
varied considerably amongst methylphenidate formulations. In 2009, the European Medicines Agency (EMA)
mandated harmonisation of methylphenidate SPCs. Between September and November 2011, there were three
changes to the atomoxetine SPC that resulted in revised prescribing information. In addition, Clinical Guidance has
also been produced by the National Institute for Health and Clinical Excellence (NICE) (2008), the Scottish
Intercollegiate Guidelines Network (SIGN) (2009) and the British National Formulary for Children (BNFC).
Methods: An updated systematic review of the Contraindications sections of the SPCs of all medications currently
licensed for treatment of ADHD in the UK was undertaken and independent statements regarding
contraindications and relevant warnings and precautions were then compared with UK national guidance with the
aim of assessing any disparity and potential areas of confusion for prescribers.
Results: As of November 2011, there were seven medications available in the UK for the treatment of ADHD.
There are 15 contraindications for most formulations of methylphenidate, 14 for dexamfetamine and 5 for
atomoxetine. Significant differences exist between the SPCs and national guidance part due to the ongoing
reactive process of amending the former as new information becomes known. In addition, recommendations are
made outside UK SPC licensed indications and a significant contraindication for methylphenidate (suicidal
behaviours) is missing from both the NICE and SIGN guidelines. Particular disparity exists relating to monitoring for
suicidal and psychiatric side effects. The BNFC has not yet been updated in line with the European Union (EU)
Directive on methylphenidate; it does not include any contraindications for atomoxetine but describes
contraindications for methylphenidate that are no longer in the SPC.
Conclusion: Clinicians seeking prescribing advice from critical independent sources of data, such as SPCs and
national guidelines, may be confused by the disparity that exists. There are major differences between guidelines
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to aid prescribing of medications for ADHD as they present the most current safety data in line with increased
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Background
Attention Deficit Hyperactivity Disorder is a commonly
diagnosed disorder affecting around 3-9% of school aged
children and young people in the UK; the worldwide
pooled prevalence rate of ADHD in the same population
is estimated at 5.29% [1,2] The number of prescriptions
written for ADHD medications in England alone has
risen significantly over time with an almost doubling of
rates from 220,000 prescriptions in 1998 to 418,300 pre-
scriptions in 2004 [3]. Data from the UK General Practice
Research Database demonstrated that the prevalence of
prescriptions in a sample of 1,636 patients increased
6.23-fold between 1999 and 2006 [4]. Associated with
increased diagnosis and treatment of ADHD is a need for
improved understanding and awareness of the safety con-
siderations detailed within the contraindications and
warnings for the various drugs licensed in the UK for
treatment of ADHD.
At the time of writing, there were eight medications
licensed in the UK to treat ADHD. These medications
were granted a marketing authorisation (license) by the
UK regulatory agency, the Medicines and Healthcare pro-
ducts Regulatory Agency (MHRA) (formerly the Medi-
cines Control Agency) following review of required
efficacy and safety data. The MHRA is a government
agency established in 2003 and is responsible for ensuring
that medicines and medical devices are effective and are
acceptably safe. Safety information is monitored from a
variety of sources and, if required, risk benefit assessments
are conducted. The MHRA initiated a risk: benefit assess-
ment for atomoxetine in 2006.
A draft SPC is submitted within the application for a
product license and is then finalised in conjunction with
the Marketing Authorisation Holder (MAH) and the reg-
u l a t o r ya g e n c yw i t ht h ep u r p o s eo fe n a b l i n gs a f ea n d
appropriate prescribing. The totality of the data reviewed
by the regulatory agency and which subsequently informs
the SPC far exceeds that which is published in the peer-
reviewed scientific literature. In summary, the SPC is the
agreed statement of known facts about a given pharma-
ceutical compound at a particular point in time and it is
critical that it is reviewed and amended regularly as new
information emerges.
Guidelines on the preparation and maintenance of
S P C sa r el a i do u tb yt h eE u r o p e a nC o m m i s s i o n( E C )
and contraindications are defined as ‘situations where
the medicinal product must not be given for safety
reasons’ [5]. Statements in the Contraindications section
of the SPC are categorical and thus hierarchically stron-
ger than those in either the Special Warnings and Pre-
cautions for Use or the Undesirable Effects sections.
The conduct of pharmacovigilance for medicines for
paediatric use requires special attention and reporting by
multiple stakeholders of potential adverse events is of
increasing importance [6]. One such stakeholder is the
MAH who is required to submit Periodic Update Safety
Reports (PSURs) to the national competent authorities
for all marketed products. The purpose of the PSUR is to
report an overview of worldwide safety experience, sum-
marise safety data within a given time period, and pro-
vide a critical evaluation of the risk: benefit balance of
the product. The PSUR captures all reports of drug safety
events considered ‘related’ to the product whether they
are reported spontaneously during clinical use or in clini-
cal trials or appear in the published literature. The PSUR
is submitted on a periodic basis, every 6 months follow-
ing approval for a period of 2 years after initial placement
on the market, then on a yearly basis for the next 2 years
(and at the renewal) and subsequently every 3 years.
However, the competent authority may require a more
frequent submission in specific cases. The review of
PSURs for atomoxetine led to three recent changes in the
prescribing information all within approximately 3
months. The first change updated the Undesirable Effects
to include anaphylactic reactions, depression and
depressed mood, anxiety and tics and pheochromocy-
toma was added as a contraindication in line with the
SPCs for methylphenidate. The next variation resulted in
amended wording to the Hepatic Warnings and Undesir-
able Effects to reflect severe liver injury cases arising
from increased exposure as a result of post-marketing
surveillance reports. The third variation arose from clini-
cal trial analysis of heart rate and blood pressure data
which has culminated in strengthened wording relating
to cardiovascular effects and the requirement to conduct
baseline and ongoing monitoring of pulse and blood
pressure and contraindications for patients with severe
cardiovascular and cerebrovascular disorders as is the
case for methylphenidate. This last change was accompa-
nied by a Dear Healthcare Professional Letter issued to
healthcare professionals in the UK in December 2011.
Because monitoring can and does lead to important
safety changes the SPC can be regarded as the current
and updated ‘ultimate guideline’ for safe and effective use
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have similar views. The US Food and Drug Administra-
tion (FDA) which is responsible for protecting the public
health by assuring the safety, efficacy and security of
drugs in the United States considers the communication
of risks and benefits through its product labelling as “the
cornerstone of risk management efforts for prescription
drugs” [7]. The SPC is thus crucial in achieving safe
prescribing.
Although the entire SPC is important, the sections
that relate to Contraindications (Section 4.3) and Special
Warnings and Precautions for Use (Section 4.4) remain
the most critical with respect to safety. Healthcare pro-
fessionals, however, are not always fully aware of the
content of SPCs, how it has been derived or how to
access them.
In April 2008, the authors presented a systematic
review of the Contraindications sections of the eight
medicines authorised in the UK at that time for the treat-
ment of ADHD in children [8]. Among the findings was
that atomoxetine, a non-stimulant treatment for ADHD,
had far fewer contraindications than stimulant medica-
tions (most commonly, formulations of methylpheni-
date). This review also identified highly varying
contraindications among the different methylphenidate
formulations despite the similar nature of the methylphe-
nidate ingredient. Whilst the reasons for this are unclear,
it may result from different MA holders submitting sepa-
rate PSURs for their respective methylphenidate contain-
ing medications. The number of contraindications for the
different presentations of methylphenidate ranged from
10-20 per formulation. All forms of methylphenidate
were contraindicated in marked anxiety/tension, diagno-
sis/family history of Tourette’s syndrome, severe angina,
arrhythmias and hyperthyroidism. Glaucoma was the
only contraindication common to all medications, stimu-
lant and non-stimulant and atomoxetine was the only
treatment with no psychiatric, cardiac or neurological
contraindications at that time.
The European Medicines Agency (EMA) is responsible
for the scientific evaluation of medicines developed by
pharmaceutical companies for use in the European Union
and constantly monitors the safety of medicines through a
pharmacovigilance network, and takes appropriate actions
if adverse drug reaction reports suggest that the risk: bene-
fit balance of a medicine has changed since it was
authorised. In 2009, the results of a full risk: benefit assess-
ment of methylphenidate-containing medications by the
EMA’s Committee for Medicinal Products for Human Use
(CHMP) under Article 31 of Directive 2001/83/EC
(amended) was published. This review was conducted due
to concerns over cardiovascular risks (hypertension, heart
rate increases and arrhythmias) and cerebrovascular risks
(migraine, cerebrovascular accident, stroke, cerebral
infarction, cerebral vasculitis and cerebral ischaemia).
Following the review, the Committee concluded there was
no need for an urgent restriction to the use of methylphe-
nidate-containing medicines, but that new recommenda-
tions on prescribing and on pre-treatment screening and
ongoing monitoring of patients were needed to maximise
the safe use of these medicines. Because information
about their safety was not consistent across the EU, the
CHMP concluded that the product information of all
methylphenidate-containing medicines authorised in the
Member States should contain the same information [9].
As a result, it was recommended that approximately 15
identical contraindications to methylphenidate be included
in the SPC of all methylphenidate formulations and har-
monised across the EU [10].
In general, prescribers in the UK are expected to follow
national guidelines to assist prescribing and for individual
cases may refer to the SPC. The aim of this systematic
review is to compare the contraindications for all medica-
tions for ADHD in the UK and to compare prescribing
advice and safety information given in the most com-
monly referred to UK ADHD guidelines with the Contra-
indications and Special Warnings and Precautions for
Use sections of the SPCs to identify any disparity that
may potentially complicate prescribing decisions.
Methods
All SPCs for medications licensed in the UK for the treat-
ment of ADHD were accessed on the electronic Medi-
cines Compendium (eMC) website (November 2011) and
the contraindications in each were tabulated. Any SPCs
not available on the eMC website were obtained directly
from the MAH. Contraindications were defined individu-
ally and copied as specified from each SPC. Where con-
traindications were markedly overlapping, they were
categorised together by the authors. The process of tabu-
lating contraindications was carried out by the lead
author and checked and reviewed by the second author.
The safety advice and recommendations provided in
two UK National Guidelines, SIGN and NICE, were
reviewed by the authors. NICE clinical guidelines make
recommendations about the treatment and care of people
with specific diseases and conditions within the National
Health Service in England and Wales and represent the
view of the Institute. They are based on publically avail-
able data. SIGN Guidelines aim to provide a framework
for evidence based assessment and management of
ADHD/Hyperkinetic Disorder (HKD) which can be
applied with a local multidisciplinary and multiagency
approach” in Scotland [11].
Both guidelines were also compared with the safety
information contained within the SPCs. Any disparity
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indications, contraindications and warnings/precautions
was tabulated.
Results
Medications
As of October 2011, there were seven medications
licensed and available in the UK for the treatment of
ADHD: atomoxetine (Strattera
®), dexamfetamine, two
short-acting preparations of methylphenidate (Ritalin
®,
Medikinet
®) and three long-acting preparations of
methylphenidate (Concerta XL
®,E q u a s y mX L
® and
Medikinet XL
®). Concerta
® XL has one SPC listed on
the eMC website for the 18-36 mg strength and one for
the 27 mg strength, although the contraindications for all
strengths are the same. Medikinet
® has one SPC listed
on the eMC website for the short-acting preparation and
two SPCs for the long-acting preparations, one covering
the 10-40 mg strengths (Medikinet XL
®) and one for the
5 mg strength (Medikinet XL
® 5 mg). The two Medikinet
XL
® SPCs are identical with respect to contraindications.
Thus, Table 1 (Licensing Information) lists the nine sepa-
rate SPCs but Table 2 (Contraindications) lists seven
SPCs, with the two Concerta XL
® SPCs and the two
Medikinet XL
® SPCs each being treated as one. One
further medication, Equasym, was removed from the
eMC website in September 2011 and is no longer avail-
able or marketed in the UK. Equasym was not considered
in this review.
Methylphenidate and atomoxetine are licensed in chil-
dren aged 6 and over and dexamfetamine is licensed for
children aged 3 and over with refractory HKD. None of
the medications are licensed to treat adults although Strat-
tera
® [12] and Concerta
® [13,14] may be used for transi-
tion into adulthood if initiated in childhood and a
favourable response to treatment has been demonstrated.
Table 1 summarises when the products were originally
licensed, the date of the latest authorisation and the date
of the most recent substantive change to the SPC. The
number of contraindications for each medication ranges
from five (Strattera
®) to 17 (Medikinet
® XL) (Table 2).
Following intervention by the EMA in January 2009
and the requirement for harmonisation of product infor-
mation within the SPCs of products containing methyl-
phenidate, the contraindications given within the SPCs
for these medications are now almost the same. However,
pronounced anacidity (absence of acidity, especially
hydrochloric acid in the gastric juices) and use with H2
blockers or antacids is unique to Medikinet
® XL [15]
while Ritalin
® [16] also contains an additional warning of
“known risk factors for cerebrovascular disorders” which
is not specified for the other short-acting methylpheni-
date formulation, Medikinet
® [17]. Although some simi-
larities exist, the 14 contraindications for dexamfetamine
[18] are quite different to those of atomoxetine and the
varying forms of methylphenidate.
UK national guidelines
The key national ADHD guidelines relating to the treat-
ment of ADHD are from NICE (2008) [1] and SIGN
(2009) [11]. The British National Formulary for Children
(BNFC), which validates its information against emerging
evidence, best-practice guidelines and a network of clinical
experts, was also reviewed [19]. The British Association
for the Psychopharmacology Transition Guidelines were
considered beyond the scope of this paper as they focus
on guiding clinicians who are specifically managing adoles-
cents with ADHD in transition from children’s services,
and adults newly presenting with ADHD [20].
The NICE recommendations for treatment differ con-
siderably from the information provided within the Indi-
cations for Treatment, Contraindications and Special
Warnings and Precautions for Use sections in the SPCs.
There is one significant conflict with the contraindica-
tions listed in all the methylphenidate SPCs; namely,
NICE 72 does not state that suicidal tendencies are a
contraindication to the use of methylphenidate. Eight
important conflicts with the warnings and precautions in
the SPCs of methylphenidate and atomoxetine were also
identified (Table 3). These include advising different
monitoring schedules of specific conditions, different
potential side effects and physical well-being from those
in the SPCs, advising potential use of methylphenidate in
the presence of stimulant misuse or risk of diversion and
recommendations for monitoring patients on atomoxe-
tine for sexual dysfunction, which is not a requirement
for children in the SPC. In addition, the use of methyl-
phenidate is advised in adults even though at the time of
the recommendation, no form of methylphenidate was
approved for use in adults. However, on June 17
th 2011,
continuation use into adulthood was added to the SPC
for Concerta
® [13,14]. Major areas of disparity arise
around the recommendations made by NICE for moni-
toring of suicidal ideation and behaviours, self-harm and
other psychiatric adverse events. Furthermore, recom-
mendations in the methylphenidate SPC for monitoring
for such psychiatric events are not included in NICE
guidelines, while prominence is given to those for
atomoxetine.
The SIGN Guidelines contain several conflicts when
compared with the Special Warnings and Precautions
for Use in the SPCs of atomoxetine, methylphenidate
and dexamfetamine. These relate to recommending use
of methylphenidate when there are known risk factors,
requirements for additional monitoring and warnings
for atomoxetine not contained in the corresponding
SPC and no mention of any monitoring requirements
for dexamfetamine (Table 4).
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Drug Date of Authorisation
(Renewal Date)
Date of Last
Substantive†
Revision to SPC
Text
Reason for Revision
Strattera
® May 2004 (May 2009) 27 September 2011 Addition of contraindication and changes to wording on cardiovascular effects, allergic events, depression, tics, anxiety and
overdose (Sections 4.3, 4.4, 4.8, 4.9 and 5.1)
3 November 2011 Change to wording on hepatic function (Sections 4.4 and 4.8)
Addition of comparator data trial outcomes (Section 5.1)
Addition of cytochrome P450 wording to Pharmacokinetic properties (Section 5.2)
25 November 2011 Addition of cardiovascular contraindication and change to wording on cardiovascular status (Sections 4.2, 4.3 and 4.4)
Ritalin
® October 1997 (April
2004)
12 May 2011 Expanded wording in the aggression and hostility warnings/overdose section relating to effects of titration from long acting
preparations (Sections 4.4, 4.9 and 10)
Concerta
® 18-36
mg
February 2002 (June
2007)
17 June 2011 Change to prescribing information relating to continuation use in adulthood (Sections 4.2, 4.4, 4.8, 5.1 and 10)
Concerta
® 27
mg
March 2007 17 June 2011
Equasym XL
® February 2005 10 October 2011 Bruxism added as a common adverse drug reaction under Undesirable Effects (Section 4.8)
Medikinet
® February 2007
(November 2008)
3 February 2010 Numerous sections updated as per article 31 Referral
Medikinet XL
®
10-40 mg
February 2007
(November 2008)
3 February 2010 Update as per article 31 Referral
Medikinet XL
® 5
mg
January 2011 24 August 2011 Addition to eMC of new SPC for new product
Dexamfetamine** October 1992 Not available Not applicable
Source: http://www.medicines.org.uk/emc/ Accessed 14 November 2011
eMC: electronic Medicines Compendium; SPC: Summary of Product Characteristics
*Relicensed to Shire
**March 2010: Sold to Auden McKenzie who do not subscribe to the eMC
†Substantive defined as any changes to prescribing information which affect safe or effective use of the medication
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2Table 2 Contraindications Listed on the SPC for Medications Licensed in the UK for ADHD
Category Non-stimulant Stimulants
Brand Name Strattera
®
Ritalin
®
Concerta
®
(18-36/27 mg)
Equasym XL
®
Medikinet
®
Medikinet XL
®
(5/10-40 mg)
Not applicable
Generic Name Atomoxetine MPH MPH MPH MPH MPH Dexamfetamine
General
Hypersensitivity X X X X X X X
(Narrow angle) Glaucoma (X) X X X X X X
With MAIOs/Within 14 days X X X X X X X
Pregnancy/lactation X
Pronounced anacidity of the
stomach
X
With H2-receptor blockers/
antacid therapy
X
Sucrose/lactose intolerances
and related disorders
X
Porphyria X
Pheochromocytoma X X X X X X
Psychiatric
Hyperexcitability X
Severe depression X X X X X
Anorexia nervosa X X X X X
Psychopatho-logical
personality structure
XX X X X
Suicidal tendency X X X X X
Psychotic symptoms X X X X X
Schizophrenia X X X X X
Mania/bipolar disorder X X X X X
Severe mood disorders X X X X X
Drug or alcohol abuse X
Endocrinological
Hyperthyroidism/
thyrotoxicosis
XX X X X X
Cardiac
Patients with severe
cardiovascular §or
cerebrovascular †disorders
whose condition would be
expected to deteriorate if
they experienced increases in
blood pressure or heart rate
that could be clinically
important
X
Pre existing cardiovascular
disorders:§*
Angina X X X X X
Life threatening
arrhythmias and
channelopathies
XX X X X
(Moderate or) Severe
hypertension
X X X X X (X)
Heart failure X X X X X
Myocardial infarction X X X X X
Arterial occlusive disease X X X X X
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for atomoxetine that are in the current SPC but reports
side effects in children which have only been reported in
clinical trials in adults; it also lists adverse events not
included in the SPC. For example, sexual dysfunction is
specifically listed as an adverse event associated with treat-
ment with atomoxetine in a publication intended to be fol-
lowed in the treatment of children but all reports of sexual
dysfunction in clinical trials relate to the treatment of
adults only and post-marketing surveillance reports of sex-
ual dysfunction for adults, children and adolescents
include only priapism and male genital pain. In addition,
the BNFC does not report the full list of contraindications
for dexamfetamine, omitting mention of Tourette’ss y n -
drome and other dystonias, sucrose and lactose intoler-
ance. Rather it lists Tourette’s syndrome as a caution not a
contraindication. The 2010/2011 BNFC was not been
updated to reflect the changes to the methylphenidate
SPCs implemented following the CHMP review in 2009.
Discussion
Since our original review of the methylphenidate SPC in
2008 [8], the CHMP has ensured a greater degree of con-
sistency across the contraindications and other prescribing
information listed in SPCs for the various formulations of
methylphenidate. One formulation of methylphenidate,
Equasym, has also been withdrawn and there have been
three significant changes to the atomoxetine SPC. In
terms of contraindications, there are numerically fewer in
the atomoxetine SPC (five) than in any of the methylphe-
nidate SPCs (maximum: 17), however, many of the specific
contraindications in the methylphenidate SPCs can be
found in the Special Warnings and Precautions for Use
section of the atomoxetine SPC and recent changes to the
contraindications for atomoxetine have made the prescrib-
ing information more similar. There remain some incon-
sistencies among the SPCs for methylphenidate although
these are unlikely to be clinically significant. Given that
atomoxetine and methylphenidate are different chemical
compounds from different classes and have different phar-
macokinetics and pharmacodynamics, it is unsurprising
that the number and type of contraindications is also dif-
ferent. It is clearly important that clinicians are aware of
the relative contraindications of all medications licensed to
treat ADHD prior to prescribing for specific patients espe-
cially those with comorbidities which may be a contraindi-
cation for treatments.
There is disparity between the three sets of UK national
guidance and the safety content and recommendations
made in the SPCs for both atomoxetine and methylpheni-
date and to a lesser extent dexamfetamine. This lack of
consistency and clarity within the information typically
used to support prescribing decisions cannot help prescri-
bers evaluate the suitability of specific medications for
individual patients. It is of interest that the respective
guidelines state that healthcare professionals are expected
to take the SPC fully into account when exercising their
clinical judgement and that the guidance does not override
the individual responsibility of healthcare professionals to
be informed by the SPC of any drugs [1].
There have been a number of initiatives in Europe and
the United States over the last 10 years designed to
increase the safety database in paediatric psychopharmacol-
ogy. Specific requirements are detailed in the Food and
Drug Administration Amendments Act of 2007 [21], while,
in 2007, the EMA enacted a new “Paediatric Regulation”
Table 2 Contraindications Listed on the SPC for Medications Licensed in the UK for ADHD (Continued)
Haemodynamically
significant congenital
heart disease
XX X X X
Cardiomyopathies X X X X X
Known risk factors for
cerebrovascular disorder
X
Structural cardiac abnormality X
Symptomatic cardiovascular
disease
X
Advanced arteriosclerosis X
Pre-existing (severe)
cerebrovascular disorders
(X)† XX X X X
Neurological
Tourette’s syndrome/similar
dystonias
X
*Categorised among pre-existing cardiovascular disorders and counted as one contraindication
§Cardiovascular conditions listed on the atomoxetine SPC as examples of severe cardiovascular disorders
†As specified and counted within cardiac contraindication for atomoxetine
ADHD: attention deficit hyperactivity disorder; MAOI: monoamine oxidase inhibitors; MPH: methylphenidate; SPC: Summary of Product Characteristics; UK: United
Kingdom
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NICE Guideline Recommendation Conflict (emphasis in bold reflects SPC)
Warn of suicidal problems and self harming behaviour with atomoxetine Suicidal problems are a contraindication to the use of methylphenidate
(omitted)
Self-harm is not listed anywhere on the atomoxetine SPC
Similar warnings are listed on SPCs for both atomoxetine and
methylphenidate
Use MPH in adults Most forms of methylphenidate are unlicensed. Atomoxetine and all
strengths of Concerta are licensed in adults who were prescribed
atomoxetine/Concerta in childhood and who continue to demonstrate a
favourable response
Use methylphenidate or atomoxetine when stimulant misuse or risk of
stimulant diversion are present
There are specific warnings on methylphenidate SPCs about risk of
misuse, diversion and related issues. In high risk cases, the advice on
methylphenidate SPCs is to use atomoxetine
Atomoxetine has no warnings or precautions relating to drug misuse
In people with ADHD, heart rate and blood pressure should be
monitored and recorded on a centile chart before and after each dose
change and routinely every 3 months
Atomoxetine and methylphenidate-Blood pressure and pulse should be
recorded on a centile chart at each adjustment of dose and then at least
every 6 months
Dexamfetamine-Blood pressure should be monitored at appropriate
intervals in all patients taking dexamfetamine, especially those with
hypertension
In people taking methylphenidate, atomoxetine, or dexamfetamine: Growth and development should be monitored during treatment with
atomoxetine
￿ height should be measured every 6 months in children and young
people
Methylphenidate-Height, weight and appetite should be recorded at
least 6 monthly with maintenance of a growth chart
￿ weight should be measured 3 and 6 months after drug treatment has
started and every 6 months thereafter in children, young people and
adults
Dexamfetamine-Height and weight should be carefully monitored in
children as growth retardation may occur
In young people and adults, sexual dysfunction (i.e., erectile and
ejaculatory dysfunction) and dysmenorrhoea should be monitored as
potential side-effects of atomoxetine
This warning is not contained within the SPC for atomoxetine. Clinical
trial data in adults shows sexual dysfunction as an undesirable effect.
Post-marketing surveillance data in children, adolescents and adults list
priapism and male genital pain as an undesirable effect
Use methylphenidate or atomoxetine with tics/Tourette’s In a controlled study of paediatric patients with ADHD and co morbid
chronic motor tics or Tourette’s Disorder, atomoxetine-treated patients
did not experience worsening of tics compared to placebo-treated
patients. There have been very rare post-marketing reports of tics in
patients taking atomoxetine). Patients who are being treated for ADHD
with atomoxetine should be monitored for the appearance or worsening
of tics
Methylphenidate is associated with the onset or exacerbation of motor
and verbal tics. Worsening of Tourette’s syndrome has also been
reported. Family history should be assessed and clinical evaluation for
tics or Tourette’s syndrome in children should precede use of
methylphenidate. Patients should be regularly monitored for the
emergence or worsening of tics during treatment with methylphenidate.
Monitoring should be at every adjustment of dose and then at least
every 6 months or every visit
Use methylphenidate or atomoxetine with anxiety disorder In two controlled studies (one in paediatric patients and one in adult
patients) of patients with ADHD and co-morbid anxiety disorders,
atomoxetine-treated patients did not experience worsening of anxiety
compared to placebo-treated patients.
There have been rare post-marketing reports of anxiety in patients taking
atomoxetine. Patients who are being treated for ADHD with atomoxetine
should be monitored for the appearance or worsening of anxiety
symptoms.
Methylphenidate is associated with the worsening of pre-existing anxiety,
agitation or tension. Clinical evaluation for anxiety, agitation or tension
should precede use of methylphenidate and patients should be regularly
monitored for the emergence or worsening of these symptoms during
treatment, at every adjustment of dose and then at least every 6 month
or every visit
In particular, those treated with atomoxetine should be closely observed
for agitation, irritability, suicidal thinking and self-harming behaviour, and
unusual changes in behaviour, particularly during the initial months of
treatment, or after a change in dose
Atomoxetine SPC-Treatment emergent agitation in children and
adolescents without a prior history of psychotic illness or mania can be
caused by atomoxetine at usual doses. Irritability is a common adverse
event but has no monitoring requirement specifically
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activity and reporting of data during the development of
medicines intended for use in children aged 0-17 years
[22]. Of relevance to ADHD is the announcement from
EMA’s European Network of Paediatric Research Group in
December 2010 of the 7
th European Commission’s Frame-
work Programme pharmacovigilance study into the long-
term adverse effects of methylphenidate in ADHD
(ADDUCE [Attention Deficit Hyperactivity Disorder Drugs
Use Chronic Effects]) and a methodological study into the
measurement of suicidality in paediatric clinical trials
(STOP [Suicidality: Treatment Occurring in Paediatrics])
[23].
Suicidality is a key area of disparity between national
guidance and SPCs. The SPC for atomoxetine specifi-
cally highlights the need for monitoring for the appear-
ance or worsening of suicide-related behaviour and
states that suicidal behaviours have occurred uncom-
monly in clinical trials. Suicide-related events are also
listed as an uncommon Undesirable Effect on the SPC.
The SPCs for methylphenidate list suicidal tendencies as
a contraindication for usage, contain a warning relating
Table 3 Differences between NICE Guidelines and SPC Content (Continued)
Methylphenidate SPCs-Psychiatric disorders to monitor for... include (but
are not limited to)... agitation, irritability. Methylphenidate is associated
with the worsening of... agitation or tension. Clinical evaluation for...
agitation or tension should precede use of methylphenidate and patients
should be regularly monitored for the emergence or worsening of these
symptoms during treatment, at every adjustment of dose and then at
least every 6 month or every visit. Irritability is a common adverse effect
of methylphenidate and patients receiving long-term therapy should be
monitored for this amongst other psychiatric adverse effects.
Suicidal ideation is an uncommon side effect on both methylphenidate
and atomoxetine SPCs. Self harm is not mentioned on either SPC
ADHD: attention deficit hyperactivity disorder; MPH: methylphenidate; NICE: National Institute for Health and Clinical Excellence; SPC: Summary of Product
Characteristics
Table 4 Differences between SIGN Guidelines and SPC Content
SIGN Guideline Recommendation Conflict (emphasis in bold reflects SPC)
Use of modified release formulations or atomoxetine should be
considered where there is likelihood of diversion
Particular warnings on methylphenidate SPC about risk of misuse,
diversion and related issues. In high risk cases, advised on
methylphenidate SPC to use atomoxetine. Atomoxetine has no such
warnings or precautions
Where atomoxetine is prescribed, clinicians should review at least 6
monthly, including assessment of ongoing efficacy and adverse effects
and measurement of growth, pulse and blood pressure (with correct
cuff size) using appropriate centile charts
Atomoxetine-Where patients are continuing treatment with atomoxetine
beyond 1 year, re-evaluation of the need for therapy by a specialist in the
treatment of ADHD is recommended. Growth and development should be
monitored during treatment with atomoxetine. Blood pressure and pulse
should be recorded on a centile chart at each adjustment of dose and
then at least every 6 months Methylphenidate- The physician who elects
to use methylphenidate for extended periods (over 12 months) in children
and adolescents with ADHD should periodically re-evaluate the long-term
usefulness of the drug for the individual patient with trial periods off
medication to assess the patient’s functioning without pharmacotherapy. It
is recommended that methylphenidate is de-challenged at least once
yearly to assess the child’s condition (preferable during times of school
holidays). Improvement may be sustained when the drug is either
temporarily or permanently discontinued. Blood pressure and pulse should
be recorded on a centile chart at each adjustment of dose and then at
least every 6 months. Height, weight and appetite should be recorded at
least 6 monthly with maintenance of a growth chart
Dexamfetamine- Blood pressure should be monitored at appropriate
intervals in all patients taking dexamfetamine, especially those with
hypertension. Height and weight should be carefully monitored in
children as growth retardation may occur
(Atomoxetine)Additional monitoring is advised for those at risk of
increased cardiovascular, hepatobiliary risk, seizure risk and potential
suicidal ideation
Atomoxetine- Blood pressure and pulse should be recorded on a centile
chart at each adjustment of dose and then at least every 6 months. No
specified requirement for hepatic or seizure monitoring.
Methylphenidate SPC-Patients on long-term therapy (i.e. over 12 months)
must have careful ongoing monitoring according to the guidance in
Sections 4.2 and 4.4 for cardiovascular status. Cardiovascular status
should be carefully monitored
ADHD: attention deficit hyperactivity disorder; MPH: methylphenidate; SIGN: Scottish Intercollegiate Guidelines Network; SPC: Summary of Product Characteristics
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cidal ideation as an uncommon Undesirable Effect. They
also mandate monitoring for all psychiatric adverse
events and this will include suicidal issues of all types.
The dexamfetamine SPC states that any family history
of suicide should be investigated prior to initiation of
treatment as part of the screening for risk of bipolar
disorder.
In contrast to the SPC content, the NICE guidelines
warn clinicians of “...suicidal problems and self harming
behaviour with atomoxetine” and make no mention of
the risks associated with other treatments. The SIGN
Guidelines repeat this disparity by stating the need to
closely monitor patients on atomoxetine in particular for
agitation, irritability, suicidal thinking and self-harming
behaviour.
The atomoxetine suicidality data are derived from a ret-
rospective analysis of atomoxetine usage in 14 paediatric
trials which reported greater suicidal ideation with ato-
moxetine when compared with placebo (p = 0.016). In a
cohort of 1,357 atomoxetine-treated subjects, there were
five cases of suicidal ideation reported, no completed sui-
cides and one suicidal attempt [24]. The same database
also reported a meta-analysis of the suicide-related events
reported from comparator studies of atomoxetine and
methylphenidate and reported no difference in rates
between these agents (Maentzel-Haentzel incidence differ-
ence -0.12 (95% confidence interval -0.62 to 0.38; p =
0.649). Hence, there would seem to be no specific data
that suggest any differential suicidality between the treat-
ments which is clearly not reflected in the National Guide-
lines. Clinical studies now include rating scales as well as
pragmatic outcome measurements to assess items such as
suicidality [25].
Similar inconsistencies arise with other sections of the
SPCs. The NICE guidelines suggest using either atomox-
etine or methylphenidate with co-morbid anxiety, but
specifically recommend the need for observation for agi-
tation or irritability only with atomoxetine despite a
strong warning on the methylphenidate SPC relating to
the need to clinically evaluate patients for agitation and
irritability prior to the use of methylphenidate. The SPC
also advises that patients should be regularly monitored
for the emergence or worsening of these symptoms dur-
ing treatment, at every adjustment of dose and then at
least every 6 month or every visit. The atomoxetine SPC
states that whilst treatment emergent agitation can be
caused by atomoxetine at usual doses there are no speci-
fic monitoring recommendations around agitation and
irritability. Methylphenidate is associated with the wor-
sening of pre-existing anxiety, agitation or tension. Clini-
cal evaluation for anxiety, agitation or tension should
precede use of methylphenidate and patients should be
regularly monitored for the emergence or worsening of
these symptoms during treatment, at every adjustment of
d o s ea n dt h e na tl e a s te v e r y6m o n t h so re v e r yv i s i t .
Recent changes to the atomoxetine SPC highlight that
anxiety was not worsened in clinical trials but that
patients being treated with atomoxetine should be moni-
tored for the appearance or worsening of anxiety. The
wording around the recommendations in the guidelines
does not fully reflect the SPC content of either product.
A similar disparity exists for usage of either agent
when tics or Tourette’s syndrome are present. Both
NICE and SIGN recommend use of either methylpheni-
date or atomoxetine although the SPCs have differences.
The atomoxetine SPC reports that there was no worsen-
ing of tics or Tourette’s in a placebo-controlled trial,
very rare post-marketing reports of tics have been
received and that patients should be monitored for the
appearance or worsening of tics. The methylphenidate
SPC states that methylphenidate is associated with the
onset of tics, that both tics and Tourette’s may worsen
with methylphenidate treatment and that clinical evalua-
tion and examination should precede methylphenidate
treatment.
Other areas of debate include adverse events attributed
to a drug. For example, in both National Guidelines, it is
recommended that sexual dysfunction is monitored in
atomoxetine patients (children and adults) but this
requirement is not reflected in the SPC. The SPC con-
tains no clinical trial data on sexual dysfunction specifi-
cally in children, only post-marketing surveillance data
which includes children, adolescents and adults.
The disparity between these independent data sources
may be complex for clinicians to interpret particularly
when the NICE guidelines recommend use of methylphe-
nidate in adults which has only been an approved indica-
tion for one form of methylphenidate (Concerta
®)s i n c e
June 2011 [13,14].
Stimulant misuse or diversion is another potential area
of concern due to the nature of ADHD. No clear gui-
dance is given in NICE despite clinical evidence that ato-
moxetine is not a drug of abuse. The methylphenidate
SPC advises clinicians to prescribe atomoxetine in high
risk cases and contains warnings and caveats about the
potential for misuse or diversion. These distinctions in
the SPCs are not translated into the guidelines.
It is frequently reported that co-morbidities are com-
mon in ADHD patients. A recent study on a cohort of
1,068 subjects with ADHD symptoms reported high rates
of Generalised Anxiety Disorder (16.8%), dysthymic dis-
order (13.5%) and Major Depressive Disorder (3%) [26]
when using the Diagnostic and Statistical Manual of
Mental Disorders, volume 4 (DSM IV). Clinicians may
thus be regularly evaluating drug choices in the presence
of significant co-morbidities and any disparity between
guidelines and SPC content may add to this complexity.
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statements as contained in the SPC and the expertise of
those routinely prescribing medications. Clinicians have
had significant experience of using methylphenidate for
many years in many children and as such have consider-
able expertise in weighing up potential tolerability and
safety risks with the benefits of medication to individual
patients. Relevant clinical publications, clinical expertise
in using the medications and achieving positive results in
cases that are contraindicated according to the SPC are
highly influential in determining future drug use. There
is experience of contraindicated medications being pre-
scribed to patients with positive outcomes despite the
potential risk of rare adverse events. The advantage of
the regulatory statements is that they are based on cumu-
lative case reports and as such reveal the rarer adverse
events that would not otherwise be picked up in routine
practice. As a consequence, appropriate levels of moni-
toring and precaution can be recommended for different
products. These types of issue are evidenced by the level
of debate in the scientific literature regarding the poten-
tial for methylphenidate to cause or worsen tics [1,10,20].
Clearly data are emerging rapidly in ADHD with the
advent of new treatments and epidemiological research
but national guidelines and SPCs cannot be updated as
frequently as data emerge. For the period from January
2009 to April 2011, the search term “atomoxetine” in
Pub Med generates 245 citations with at least 94 citations
likely to contain clinical data, meta-analyses or reviews.
The future safety of paediatric treatments are paramount
and are likely to be advanced by the FDA and EMA regu-
lations and the ability of large databases to address out-
come measures of a more pragmatic kind. Some safety
aspects may even be improved by drug treatment. Recent
data on atomoxetine usage in a cohort of 13-16 year old
children improving unhealthy dietary behaviours and
physical activity as well as reducing behaviours contribut-
ing to unintentional injuries [27].
To be able to make prescribing decisions based on
sound evidence, clinicians need to be aware of, and be
familiar with, the different sources of information avail-
able to them. The SPC, as an independent document
reflecting current knowledge, may be the best way of
achieving this.
Conclusion
Clinicians seeking guidance regarding the use of medica-
tions for ADHD in UK will find significant disparity
between relevant national guidance and SPCs; these dif-
ferences extend to licensed indications, contraindica-
tions, warnings and precautions and monitoring
schedules. The contraindications sections within the
SPC provide clear categorical statements for which the
relevant medications should not be prescribed.
In view of the approval of the content of the SPC by
the regulatory agency and the ongoing changes that take
place to reflect current safety findings, many of which
have been discussed in this manuscript, clinicians may
be advised to consider the SPC as the ultimate guideline.
The very recent decision by NICE not to update the
current ADHD Guideline until 2014 may further
increase the relevance of the respective SPCs.
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